Aprepitant
Contraindicated
Textbook
Increased plasma levels and toxicity of cilostazole.
Should not be administered along with inhibitors of CYP3A4.
Source: KDT 7e · p555
Drug reference
cilostazole
PDE-3 inhibitor · Peripheral vasodilator, Antiplatelet
PDE-3 inhibitorPeripheral vasodilator, Antiplatelet
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
incl. contraindicated
PREGNANCY
—
not curated
Top interactionssee all 12 →
- AprepitantContraindicatedTextbookKDT 7e · p555
- CiprofloxacinContraindicatedTextbookKDT 7e · p555
- ClarithromycinContraindicatedTextbookKDT 7e · p555
- CobicistatContraindicatedTextbookKDT 7e · p555
Mechanism
PDE-3 inhibitor which increases intracellular cAMP in platelets and vascular smooth muscle resulting in antiaggregatory and vasodilator effects.
Indications
Intermittent claudication (in patients with no rest pain or heart failure)
Dosing
- Adult
- 100 mg BD, 30 min before or 2 hour after food
Pharmacokinetics
Half-life
approximately 12 hours
Metabolism
extensively metabolized by CYP3A4 and CYP2C19 into active and inactive metabolites
Excretion
in urine
Contraindications
- patients with heart failure
- patients who have pain even at rest
- patients with tissue necrosis
- inhibitors of CYP3A4
- inhibitors of CYP2C19
Side effects
Common
headachepalpitationdizzinessnauseavomitingweaknessincrease in ventricular ectopics or nonsustained VT
Drug interactions
Ciprofloxacin
Contraindicated
Textbook
Increased plasma levels and toxicity of cilostazole.
Should not be administered along with inhibitors of CYP3A4.
Source: KDT 7e · p555
Clarithromycin
Contraindicated
Textbook
Increased plasma levels and toxicity of cilostazole.
Should not be administered along with inhibitors of CYP3A4.
Source: KDT 7e · p555
Cobicistat
Contraindicated
Textbook
Increased plasma levels and toxicity of cilostazole.
Should not be administered along with inhibitors of CYP3A4.
Source: KDT 7e · p555
Cyp2c19 Inhibitors
Contraindicated
Textbook
Increased plasma levels and toxicity of cilostazole.
Should not be administered along with inhibitors of CYP2C19.
Source: KDT 7e · p555
Diltiazem
Contraindicated
Textbook
Increased plasma levels and toxicity of cilostazole.
Should not be administered along with inhibitors of CYP3A4.
Source: KDT 7e · p555
Erythromycin
Contraindicated
Textbook
Increased plasma levels and toxicity of cilostazole.
Should not be administered along with inhibitors of CYP3A4.
Source: KDT 7e · p555
Fluconazole
Contraindicated
Textbook
Increased plasma levels and toxicity of cilostazole.
Should not be administered along with inhibitors of CYP3A4.
Source: KDT 7e · p555
Imatinib
Contraindicated
Textbook
Increased plasma levels and toxicity of cilostazole.
Should not be administered along with inhibitors of CYP3A4.
Source: KDT 7e · p555
Indinavir
Contraindicated
Textbook
Increased plasma levels and toxicity of cilostazole.
Should not be administered along with inhibitors of CYP3A4.
Source: KDT 7e · p555
Itraconazole
Contraindicated
Textbook
Increased plasma levels and toxicity of cilostazole.
Should not be administered along with inhibitors of CYP3A4.
Source: KDT 7e · p555
Ketoconazole
Contraindicated
Textbook
Increased plasma levels and toxicity of cilostazole.
Should not be administered along with inhibitors of CYP3A4.
Source: KDT 7e · p555
Related guidelines
Ask House about cilostazole
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e·Verified: 2026-05-10 · House clinical team